Search research articles
Contact Us
Filters
Showing results (1-10 of 74) with videos related to
Page
of 8
Sort By:
World Journal of Microbiology & Biotechnology
|
April 6, 2017
Microbial production of nattokinase: current progress, challenge and prospect
Dongbo Cai, Chengjun Zhu, Shouwen Chen
Journal for Immunotherapy of Cancer
|
April 30, 2025
Tumor-infiltrating mast cells as potential chemoimmunotherapy enhancer in triple-negative breast cancer
Pinchao Fan, Chengjun Zhu, Xiaoxiang Guan
Cancer Letters
|
November 14, 2025
Current landscape of cross-line immune checkpoint blockade for cancer treatment
Pinchao Fan, Jing Wu, Chengjun Zhu, et al.
Applied and Environmental Microbiology
|
November 22, 2011
Development of a new strategy for production of medium-chain-length polyhydroxyalkanoates by recombinant Escherichia coli via inexpensive non-fatty acid feedstocks
Qin Wang, Ryan C Tappel, Chengjun Zhu, et al.
Clinical Breast Cancer
|
March 25, 2023
Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer
Yue Sun, Chengjun Zhu, Feng Xu, et al.
The Breast Journal
|
June 20, 2026
Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis
Dandan Yu, Chengjun Zhu, Sujin Yang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|
December 19, 2017
Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-Β1 Expression in Macrophage
Chengjun Zhu, Hua Shen, Lingjun Zhu, et al.
Pathology, Research and Practice
|
March 2, 2020
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma
Chengjun Zhu, Lu Jiang, Jun Xu, et al.
The Oncologist
|
November 16, 2024
Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis
Ke Wang, Ting Xu, Jing Wu, et al.
Translational Cancer Research
|
February 4, 2022
Expression of <i>CDK7</i> correlates with molecular subtypes and predicts clinical outcomes in breast cancer
Lin Tang, Chengjun Zhu, Juan Jin, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 74) with videos related to
Sort By:
Page
of 8
World Journal of Microbiology & Biotechnology
|
April 6, 2017
Microbial production of nattokinase: current progress, challenge and prospect
Dongbo Cai, Chengjun Zhu, Shouwen Chen
Journal for Immunotherapy of Cancer
|
April 30, 2025
Tumor-infiltrating mast cells as potential chemoimmunotherapy enhancer in triple-negative breast cancer
Pinchao Fan, Chengjun Zhu, Xiaoxiang Guan
Cancer Letters
|
November 14, 2025
Current landscape of cross-line immune checkpoint blockade for cancer treatment
Pinchao Fan, Jing Wu, Chengjun Zhu, et al.
Applied and Environmental Microbiology
|
November 22, 2011
Development of a new strategy for production of medium-chain-length polyhydroxyalkanoates by recombinant Escherichia coli via inexpensive non-fatty acid feedstocks
Qin Wang, Ryan C Tappel, Chengjun Zhu, et al.
Clinical Breast Cancer
|
March 25, 2023
Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer
Yue Sun, Chengjun Zhu, Feng Xu, et al.
The Breast Journal
|
June 20, 2026
Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis
Dandan Yu, Chengjun Zhu, Sujin Yang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|
December 19, 2017
Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-Β1 Expression in Macrophage
Chengjun Zhu, Hua Shen, Lingjun Zhu, et al.
Pathology, Research and Practice
|
March 2, 2020
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma
Chengjun Zhu, Lu Jiang, Jun Xu, et al.
The Oncologist
|
November 16, 2024
Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis
Ke Wang, Ting Xu, Jing Wu, et al.
Translational Cancer Research
|
February 4, 2022
Expression of <i>CDK7</i> correlates with molecular subtypes and predicts clinical outcomes in breast cancer
Lin Tang, Chengjun Zhu, Juan Jin, et al.
Page
of 8